Clinical Certificate


Date: Thursday 2nd May 2019 – Friday 3rd May 2019
Venue: Victoria and Albert Hotel, Water St, Manchester, M3 4JQ
Accommodation: Victoria and Albert Hotel, Water St, Manchester , M3 4JQ
(accommodation is bookable separately when you complete the online booking form)
Organised by: Professor Jo Neill and Dr Richard Drake
Booking Status: FULLY BOOKED. Please email to be placed on the waiting list.


Thursday 2 May
10:00–10:30 Arrival, Registration and Coffee
10:30–10:35 Introduction
Professor Jo Neill (Manchester)
10:35–11:10 Causes of schizophrenia: Introduction to current thinking
Professor Shôn Lewis (Manchester)
11:10–12:00 Pharmacology of antipsychotic medication
Professor Rachel Upthegrove (Birmingham)
12:00–12:10 Q&A session
12:10–12:45 New trial data and clinical guidelines
Professor Shôn Lewis
12:45–12:55 Q&A session
13:00–13:45 Lunch in the Restaurant
13:45–14:35 Recent developments in the psychopharmacological understanding of schizophrenia
Professor Bill Deakin (Manchester)
14:35–14:50 Q&A session
14:50–15:20 Pharmacogenomics: impact on efficacy, side effects and adverse drug reactions (& drug interactions)
Professor Jo Neill
15:20–15:30 Q&A session
15:30–16:00 Refreshments and delegates split into 3 groups
16:00–17:30 Group Work – Split into three groups
Group A: Treatment Problems
Dr Richard Drake (Manchester)
Group B: Treatment Problems
Professor Rachel Upthegrove
Group C: Treatment Problems
Professor David Owens (Edinburgh)
17:30 End of Thursday Sessions
Friday 3 May
08:30–08:45 Arrival and Coffee
08:45–09:30 Antipsychotics and relapse prevention in schizophrenia
Professor Thomas Barnes (London)
09:30–09:45 Q&A session
09:45–10:15 Refreshments
10:15–10:55 Adverse effects of antipsychotics
Dr Maxine Patel (London)
10:55–11:15 Q&A session
11:15–12:15 Pharmacological strategies for treatment-resistant schizophrenia
Professor Thomas Barnes (London)
12:15–12:30 Q&A session
12:30–13:20 Lunch in the Restaurant
13:20–14:20 EPS Update
Professor David Owens (Edinburgh)
14:20–14:35 Q&A session
14:35–15:05 Everything you ever wanted to know about first generation antipsychotics but were afraid to ask
Dr Richard Drake (Manchester)
15:05–15:15 Q&A session
15:15 Meeting ends. Return of evaluation forms

Last edited 11th March 2019

Learning Objectives

At the end of this module, the attendees will:

  • Be aware of current theories of the causes and neurochemistry of schizophrenia
  • Know the pharmacology of conventional and atypical drugs
  • Be aware of the clinical assessment of therapeutic and adverse effects
  • Have an opinion about relative benefits of conventional and atypical drugs
  • Be updated on guidelines and the social context of drug prescribing in schizophrenia
  • Have had an opportunity to discuss difficult management problems with colleagues and experts

This module is eligible for 11 CPD hours which are subject to peer group review.

For further details contact Susan Chandler, BAP Executive Officer:

Feedback from 2018 Module

"Excellent course – very well organized, presentations by superb speakers on a single illness. A really in-depth course for schizophrenia"

"A truly maximum value for money and time course. The focus on science and research makes the talks fascinating and compelling"

"Very useful, I will encourage higher trainees in psychiatry to attend this"

"Very well structured meeting; stimulating with excellent speakers. I feel inspired!"

"Another fantastic BAP module. Very helpful and relevant"

Print DOIs